Logo

Santhera’s Agamree (vamorolone) Receives the US FDA’s Approval for the Treatment of Duchenne Muscular Dystrophy (DMD)

Share this
Santhera

Santhera’s Agamree (vamorolone) Receives the US FDA’s Approval for the Treatment of Duchenne Muscular Dystrophy (DMD)

Shots:

  • The approval was granted based on the data from the P-IIb (VISION-DMD) clinical trial evaluating the safety & efficacy of Agamree (2-6mg/kg/day) vs SoC corticosteroids in patients with DMD for up to 48mos. across 32 clinical trials in 11 countries
  • As per the agreement between Santhera & Catalyst Pharmaceuticals, following the approval, Santhera will receive $36M ($10M as milestone payments + $26M to cover contracted third-party milestone obligations) from Catalyst. Additionally, the US marketing authorization of Agamree will be transferred to Catalyst which expects to launch Agamree across the US in Q1’24
  • Santhera also received a positive opinion from the CHMP for which the EMA approval is expected by YE 2023

Ref: Santhera | Image: Santhera

Related News:- Santhera Receives the EMA’s CHMP Positive Opinion of Agamree (vamorolone) for the Treatment of Duchenne Muscular Dystrophy

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com

Click here to­ read the full press release 

Shivani Chandra

Shivani was a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She was covering news related to Product approvals, clinical trial results, and updates. We can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions